{"id":574,"date":"2018-04-20T19:48:08","date_gmt":"2018-04-20T19:48:08","guid":{"rendered":"http:\/\/haema-journal.gr\/?p=574"},"modified":"2018-04-25T18:36:33","modified_gmt":"2018-04-25T18:36:33","slug":"targeted-therapy-in-hodgkin-lymphoma-clinical-aspects","status":"publish","type":"post","link":"https:\/\/haema-journal.gr\/?p=574","title":{"rendered":"Targeted therapy in Hodgkin lymphoma &#8211; Clinical aspects"},"content":{"rendered":"<p style=\"text-align: right;\"><em>Haema 2012; 3(3): 260-265<\/em><\/p>\n<p>by Ioannis Kotsianidis, \u0395mmanouil Spanoudakis, Konstantinos Tsatalas<\/p>\n<p>Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece<\/p>\n<p style=\"text-align: right;\"><a href=\"http:\/\/haema-journal.gr\/PDF\/2012\/HAEMA_2012-260.pdf\" target=\"_blank\" rel=\"noopener\">Full PDF (in Greek)<\/a> | <a href=\"http:\/\/haema-journal.gr\/PDF\/2012\/HAEMA_2012-260.pdf\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-390 size-full\" src=\"http:\/\/haema-journal.gr\/wp-content\/uploads\/2018\/02\/PDF-icon.jpg\" alt=\"\" width=\"36\" height=\"36\" \/><\/a><\/p>\n<p><!--more--><\/p>\n<h5><strong>Abstract<\/strong><\/h5>\n<p style=\"text-align: justify;\">Hodgkin\u2019s lymphoma is one of the first cancers to be rendered curable by combination chemotherapy. Adriamycin, bleomycin, vinblastine, dacarbazine (ABVD) is considered as the standard of care for most patients as it offers an excellent balance of efficacy and toxicity. However, though the majority of patients can be cured with ABVD or alternative regimens even in advanced stages, recurrent and refractory disease remains a significant problem. Additionally, long-term toxicity is becoming a major issue, as survivors cured of Hodgkin\u2019s lymphoma outnumber the patients with active disease. Advances in our understanding of the pathobiology of the disease culminated in the development of novel targeted therapies, many of which have demonstrated remarkable activity in the relapsed\/refractory setting and are currently investigated as frontline treatment.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Haema 2012; 3(3): 260-265 by Ioannis Kotsianidis, \u0395mmanouil Spanoudakis, Konstantinos Tsatalas Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece Full PDF (in Greek) |<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[43],"tags":[],"class_list":["post-574","post","type-post","status-publish","format-standard","hentry","category-haema-2012-3"],"_links":{"self":[{"href":"https:\/\/haema-journal.gr\/index.php?rest_route=\/wp\/v2\/posts\/574","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haema-journal.gr\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haema-journal.gr\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haema-journal.gr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haema-journal.gr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=574"}],"version-history":[{"count":4,"href":"https:\/\/haema-journal.gr\/index.php?rest_route=\/wp\/v2\/posts\/574\/revisions"}],"predecessor-version":[{"id":1004,"href":"https:\/\/haema-journal.gr\/index.php?rest_route=\/wp\/v2\/posts\/574\/revisions\/1004"}],"wp:attachment":[{"href":"https:\/\/haema-journal.gr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=574"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haema-journal.gr\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=574"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haema-journal.gr\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=574"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}